Janux Therapeutics Valuation
| JANX Stock | USD 46.39 1.61 3.35% |
At this time, the firm appears to be overvalued. Janux Therapeutics retains a regular Real Value of $39.9 per share. The prevalent price of the firm is $46.39. Our model calculates the value of Janux Therapeutics from evaluating the firm fundamentals such as Shares Outstanding of 52.48 M, return on equity of -0.12, and Return On Asset of -0.0993 as well as inspecting its technical indicators and probability of bankruptcy. Key fundamental drivers impacting Janux Therapeutics' valuation include:
Price Book 3.7108 | Enterprise Value 1.8 B | Enterprise Value Ebitda (33.80) | Price Sales 186.5767 | Enterprise Value Revenue 137.9447 |
Overvalued
Today
Please note that Janux Therapeutics' price fluctuation is very steady at this time. Calculation of the real value of Janux Therapeutics is based on 3 months time horizon. Increasing Janux Therapeutics' time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
Since Janux Therapeutics is currently traded on the exchange, buyers and sellers on that exchange determine the market value of Janux Stock. However, Janux Therapeutics' intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 46.39 | Real 39.9 | Target 27.25 | Hype 46.39 | Naive 48.83 |
The intrinsic value of Janux Therapeutics' stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, news, and other external factors that may influence Janux Therapeutics' stock price. It is important to note that the real value of any stock may change over time based on changes in the company's performance.
Estimating the potential upside or downside of Janux Therapeutics helps investors to forecast how Janux stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Janux Therapeutics more accurately as focusing exclusively on Janux Therapeutics' fundamentals will not take into account other important factors: Traditionally, analysts and sophisticated investors use multiple methods for valuing a cash-flow-generating entity or its stock. For example, some money managers use Janux Therapeutics' intrinsic value based on its ongoing forecasts of Janux Therapeutics' financial statements. In contrast, other private, professional wealth advisors use a multiplier approach by looking to relative value analysis against Janux Therapeutics' closest peers.
Janux Therapeutics Cash |
|
Janux Valuation Trend
Analysing the historical paterns of Janux Therapeutics' enterprise value and its market capitalization is a good way to estimate and gauge the value of Janux Therapeutics over time and is usually enough for investors to make rational market timing decisions.
Janux Therapeutics Total Value Analysis
Janux Therapeutics is currently estimated to have valuation of 1.8 B with market capitalization of 2.43 B, debt of 24.54 M, and cash on hands of 338.76 M. Please note that valuation may be misleading and is a subject to auditing or accounting errors. We encourage investors to vigilantly validate all of the Janux Therapeutics fundamentals before making equity appraisal based on enterprise value of the company| Takeover Price | Market Cap | Debt Obligations | Cash |
1.8 B | 2.43 B | 24.54 M | 338.76 M |
Janux Therapeutics Investor Information
About 95.0% of the company shares are owned by institutional investors. The book value of Janux Therapeutics was currently reported as 12.54. The company recorded a loss per share of 1.17. Janux Therapeutics had not issued any dividends in recent years. Based on the key indicators related to Janux Therapeutics' liquidity, profitability, solvency, and operating efficiency, Janux Therapeutics is not in a good financial situation at this time. It has a very high odds of going through financial crisis in December.Janux Therapeutics Asset Utilization
The asset utilization indicator refers to the revenue earned for every dollar of assets a company currently reports. Janux Therapeutics has an asset utilization ratio of 2.12 percent. This suggests that the Company is making $0.0212 for each dollar of assets. An increasing asset utilization means that Janux Therapeutics is more efficient with each dollar of assets it utilizes for everyday operations.Janux Therapeutics Ownership Allocation
Janux Therapeutics has a total of 52.48 Million outstanding shares. The majority of Janux Therapeutics outstanding shares are owned by outside corporations. These institutional investors are usually referred to as non-private investors looking to purchase positions in Janux Therapeutics to benefit from reduced commissions. Consequently, third-party entities are subject to a different set of regulations than regular investors in Janux Therapeutics. Please pay attention to any change in the institutional holdings of Janux Therapeutics as this could imply that something significant has changed or is about to change at the company. Also note that almost one million two hundred seventeen thousand five hundred eighty-two invesors are currently shorting Janux Therapeutics expressing very little confidence in its future performance.Janux Therapeutics Profitability Analysis
The company reported the previous year's revenue of 8.08 M. Net Loss for the year was (58.29 M) with loss before overhead, payroll, taxes, and interest of (44.83 M).About Janux Therapeutics Valuation
Our relative valuation model uses a comparative analysis of Janux Therapeutics. We calculate exposure to Janux Therapeutics's market risk, different technical and fundamental indicators, and relevant financial multiples and ratios and then compare them to those of Janux Therapeutics's related companies.| Last Reported | Projected for Next Year | ||
| Gross Profit | 6.1 M | 4 M | |
| Pretax Profit Margin | (7.21) | (7.57) | |
| Operating Profit Margin | (9.03) | (9.48) | |
| Net Loss | (7.21) | (7.57) | |
| Gross Profit Margin | 0.76 | 0.97 |
Janux Therapeutics Growth Indicators
Growth stocks usually refer to those companies expected to grow sales and earnings faster than the market average. Growth stocks typically don't pay dividends, often look expensive, and usually trading at a high P/E ratio. Nevertheless, such valuations could be relatively cheap if the company continues to grow, which will drive the share price up. However, since most investors are paying a high price for a growth stock, based on expectations, if those expectations are not fully realized, growth stocks can see dramatic declines.
| Common Stock Shares Outstanding | 44 M |
Janux Therapeutics Current Valuation Indicators
Valuation refers to the process of determining the present value of Janux Therapeutics and all of its assets. It can be calculated using a number of techniques. As many analysts who try to value Janux we look at many different elements of the entity such as Janux's management, its prospective future earnings, the current market value of the company's assets, as well as its capital structure formation.
Valuations are an essential part of business, for companies themselves, but also for investors. For companies, such as Janux Therapeutics, valuations can help measure their progress and success and can help them track their performance in the market compared to others. In addition, investors can use Janux Therapeutics' valuations to help determine the worth of potential investments. They can do this by using data and information made public by a company. Regardless of who the valuation is for, it essentially describes Janux Therapeutics' worth.Additional Tools for Janux Stock Analysis
When running Janux Therapeutics' price analysis, check to measure Janux Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Janux Therapeutics is operating at the current time. Most of Janux Therapeutics' value examination focuses on studying past and present price action to predict the probability of Janux Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Janux Therapeutics' price. Additionally, you may evaluate how the addition of Janux Therapeutics to your portfolios can decrease your overall portfolio volatility.